AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12630027
Drug: Interferon alone
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alone (natural interferon‐beta 6 MU daily for 6 weeks and thrice‐a‐week for 20 weeks) for 26 weeks
Trial: 1673324
Drug: Esmolol (less
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (less than or equal to 24 mg/min)
Trial: 7060824
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg triamcinolone hexacetonide (TH)
Trial: 7060824
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg methylprednisolone (MP)
Trial: 7060824
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg betamethasone (BM)
Trial: 16170078
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human IL-1 receptor antagonist (rhIL-1ra)
Trial: 12049374
Drug: Metoprolol or
RxNorm normalized name: metoprolol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol or Propranolol (maximal tolerated dose, 28 patients, group A, 86±23 vs 98±29 mg/d)
Trial: 12049374
Drug: No pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pharmacological therapy (28 patients, group B)
Trial: 12049374
Drug: No pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pharmacological therapy (group B)
Trial: 12049374
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (beta-blockers)
Trial: 9508205
Drug: Granisetron 3
RxNorm normalized name: granisetron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 3 mg i.v. plus dexamethasone 10 mg i.v. prechemotherapy followed by granisetron 1 mg orally at 6 and 12 hours, then granisetron 1 mg orally and dexamethasone 8 mg orally twice daily on days 2 through 7
Trial: 31711921
Drug: Etrasimod 1
RxNorm normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrasimod 1 mg
Trial: 20546271
Drug: Supper (15-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supper (15-g carbohydrate dairy snack before bed)
Trial: 15865113
Drug: Preoperative radiology
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiology (intravenous cholangiography or magnetic resonance cholangiography)
Trial: 12848204
Drug: Protocol A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol A: Fluid restriction, avoidance of routine sedation, higher doses of mannitol
Trial: 12848204
Drug: Unrestricted fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unrestricted fluid supplementation, routine sedation, lower doses of mannitol (only when needed) for GCS ≤ 8
Trial: 9202359
Drug: HMG‐CoA reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMG‐CoA reductase inhibitors
Trial: 3327846
Drug: 400 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/kg body weight of i.v. IgG on 5 consecutive alternate days and subsequently after 15 days and monthly thereafter for up to six months
Trial: 27550953
Drug: Lenalidomide 10
RxNorm normalized name: lenalidomide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 10 mg once daily for 12 weeks
Trial: 11549103
Drug: Combined doses
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined doses of piperacillin and tobramycin
Trial: 9549737
Drug: Late cannulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late cannulation (Group L)
Trial: 26596627
Drug: Infliximab (IFX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (IFX), a single intravenous injection of 3 mg/kg
Trial: 26596627
Drug: Placebo, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, a single saline serum injection
Trial: 23945572
Drug: Simplified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simplified treatment regimens for severe infection
Trial: 1512328
Drug: Alteplase (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (10 mg bolus, then 90 mg over 2 h) followed by heparin
Trial: 1512328
Drug: Heparin (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (continuous infusion rate of 1,750 IU/h)
Trial: 6240405
Drug: PN 200-110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PN 200-110 (2.5 mg, 5.0 mg, 10.0 mg)
Trial: 23250532
Drug: Local immunomodulator
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local immunomodulator (0.04% synthetic tetradecapeptide solution)
Trial: 20462428
Drug: 42 g
RxNorm normalized name: PETROLATUM 42 g in 100 g TOPICAL OINTMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 42 g raw walnuts/d for 6 weeks
Trial: 20462428
Drug: 21 g
RxNorm normalized name: Long's Lancets, 21 ga
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 g raw walnuts/d for 6 weeks
Trial: 18765001
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone gel (90 mg, once daily)
Trial: 18765001
Drug: Vaginal micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal micronized progesterone tablets (200 mg, three times daily)
Trial: 11019474
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment (day care)
Trial: 11019474
Drug: Inpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient treatment (hospital admission)
Trial: 11019474
Drug: Overall acceptability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall acceptability of outpatient treatment
Trial: 2334155
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of norfloxacin alone
Trial: 2334155
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of norfloxacin 5 min after aluminum‐magnesium hydroxide (Maalox)
Trial: 2334155
Drug: Maalox 2
RxNorm normalized name: Gas-X with Maalox 250 MG / 62.5 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maalox 2 h after 400 mg of norfloxacin
Trial: 2334155
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of norfloxacin 5 min after calcium carbonate (Titralac)
Trial: 2334155
Drug: Antacid administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid administration
Trial: 31101323
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers (after excluding patients with prior myocardial infarction or heart failure)
Trial: 28588686
Drug: Continuous renal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous renal replacement therapy (CRRT) for 24 hours
Trial: 23995030
Drug: Pharmacotherapy (paroxetine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (paroxetine)
Trial: 19210949
Drug: Brief cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive-behavioral therapy (CBT)
Trial: 11052924
Drug: Retinyl palmitate
RxNorm normalized name: Retinyl palmitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinyl palmitate (RP) 400000 i.u. administered intramuscularly to 6 patients
Trial: 1341892
Drug: OK-432 (1KE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OK-432 (1KE or 5KE) administered one or 3 times every other day
Trial: 1341892
Drug: OK-432 (repeated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OK-432 (repeated injections)
Trial: 1341892
Drug: OK-432 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OK-432 (doses more than 5 KE)
Trial: 29480440
Drug: Weekly short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly short-term lotteries for 13 weeks
Trial: 26995281
Drug: 12-month digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month digital health weight loss intervention including algorithm-generated tailored behavior change goals, self-monitoring via mobile technologies, daily self-weighing using a network-connected scale, skills training materials, 18 counseling phone calls with a Track coach, and primary care provider counseling.
Trial: 10639654
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (verbal and written advice and exercises)
Trial: 11540403
Drug: 5 mg/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/70 kg d-methamphetamine
Trial: 11540403
Drug: 10 mg/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/70 kg d-methamphetamine
Trial: 1858618
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (group I)
Trial: 28292304
Drug: iCPR tool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iCPR tool with academic detailing about strep pharyngitis and pneumonia diagnosis and treatment
Trial: 28292304
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with academic detailing about strep pharyngitis and pneumonia diagnosis and treatment
Trial: 27004425
Drug: GS-9190 single
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-9190 single dose
Trial: 27004425
Drug: GS-9190 multiple
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-9190 multiple doses (8 days)
Trial: 27004425
Drug: GS-9190 multiple
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-9190 multiple doses (4-6 months follow-up)
Trial: 20190467
Drug: Risedronate monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate monotherapy (n=8)
Trial: 20190467
Drug: Combined risedronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined risedronate and vitamin K(2) therapy (n=8)
Trial: 20190467
Drug: Intravenous steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous steroid pulse therapy (n=6, group C)
Trial: 15681523
Drug: Capecitabine (2,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (2,500 mg/m2/d)
Trial: 15681523
Drug: Capecitabine plus
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine plus Bevacizumab (15 mg/kg)
Trial: 1663853
Drug: EPO to
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO to achieve a hemoglobin of 95-110 g/L
Trial: 1663853
Drug: EPO to
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO to achieve a hemoglobin of 115-130 g/L
Trial: 1663853
Drug: EPO therapy
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO therapy (both dosages)
Trial: 31694684
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine with paravertebral saline
Trial: 31694684
Drug: Paravertebral lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paravertebral lidocaine with intravenous saline
Trial: 31694684
Drug: Intravenous remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous remifentanil with paravertebral saline
Trial: 19833260
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg, followed by 80 mg
Trial: 19833260
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg, followed by 80 mg
Trial: 19833260
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg, followed by 40 mg
Trial: 19833260
Drug: Gene-dose effect
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Gene-dose effect
Trial: 17537739
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment by hospital and primary care staff
Trial: 11519773
Drug: Micronized progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized progesterone (MP) 200 mg
Trial: 11519773
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 5 mg
Trial: 8010466
Drug: Late administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late administration of epidural analgesia (after 5 cm dilation) with prior intravenous nalbuphine (10 mg)
Trial: 2686320
Drug: Sinestrol 1
RxNorm normalized name: dienestrol 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinestrol 1 mg orally twice a day for 3 weeks
Trial: 28855417
Drug: Methionine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intake (0, 5, 10, 15, 25, and 35 mg · kg‐1 · d‐1) with no Cys in the diet
Trial: 28855417
Drug: Methionine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intake (0, 2.5, 5, 7.5, 10, and 15 mg · kg‐1 · d‐1) with 21 mg · kg‐1 · d‐1 Cys
Trial: 26860015
Drug: Bupivacaine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (1 mg/kg)
Trial: 19505304
Drug: ASAQ orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASAQ orally once daily (ASAQ1)
Trial: 19505304
Drug: ASAQ twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASAQ twice daily (ASAQ2)
Trial: 19505304
Drug: Artemether +
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artemether + lumefantrine (AL) twice daily
Trial: 15510758
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation of ferrous sulfate (200 mg) for 2 months
Trial: 15510758
Drug: Weekly supplementation
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly supplementation of ferrous sulfate (200 mg) for 2 months
Trial: 2190251
Drug: Methylphenidate infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate infusion
Trial: 29806872
Drug: XR-NTX (380
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XR-NTX (380 mg intramuscular injections every fourth week)
Trial: 24247300
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine (2 μg/kg/min)
Trial: 24247300
Drug: Low-dose nesiritide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose nesiritide (0.005 μg/kg/min without bolus)
Trial: 21173349
Drug: Mechanical valve
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical valve replacement with optimal self-management anticoagulation therapy
Trial: 18158199
Drug: Betamethasone oral
RxNorm normalized name: betamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone oral mini-pulse (OMP) therapy (5 mg orally on 2 consecutive days per week for 3 months)
Trial: 18158199
Drug: Topical triamcinolone
RxNorm normalized name: triamcinolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical triamcinolone acetonide (0.1%) paste (applied thrice daily for 3 months)
Trial: 10972608
Drug: etomidate, 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etomidate, 0.2 mg/kg (intravenous group)
Trial: 1532760
Drug: General practitioner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General practitioner treatment
Trial: 22219405
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment, 94 patients)
Trial: 20591399
Drug: ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranibizumab (0.5 mg/0.05 mL)
Trial: 11898244
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of medications (control)
Trial: 8814094
Drug: 3 years
RxNorm normalized name: NanoVM 1-3 years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 years treatment
Trial: 8814094
Drug: 1 year
RxNorm normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 year treatment
Trial: 6703855
Drug: Amitriptyline (N
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (N = 5) after abrupt cessation of therapy
Trial: 6703855
Drug: Desipramine after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine after abrupt cessation of therapy
Trial: 31273750
Drug: Experimental agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental agent with adaptive randomization and dose-schedule regimes
Trial: 27440189
Drug: Web-based Acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based Acceptance and Commitment Therapy (ACT)
Trial: 25433006
Drug: Temocillin administered
RxNorm normalized name: temocillin
DrugBank: Temocillin (DB12343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocillin administered three times daily (6 g daily)
Trial: 25433006
Drug: Temocillin administered
RxNorm normalized name: temocillin
DrugBank: Temocillin (DB12343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocillin administered by continuous infusion (6 g daily)
Trial: 25433006
Drug: Temocillin administered
RxNorm normalized name: temocillin
DrugBank: Temocillin (DB12343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocillin administered by continuous infusion (750 mg daily) in patients undergoing CVVH
Trial: 19296044
Drug: MBP group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBP group (40 mg MBP for 8 months)
Trial: 15534479
Drug: Contact-topical anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contact-topical anesthesia
Trial: 8145904
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (saline placebo)
Trial: 26939320
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional western medicine)
Trial: 22998456
Drug: Chlorhexidine 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine 1% gel
Trial: 20926135
Drug: Triamcinolone treatment
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone treatment for CRVO
Trial: 19735519
Drug: Juvéderm injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juvéderm injectable gel with lidocaine (JUV + L)
Trial: 19735519
Drug: Juvéderm injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juvéderm injectable gel without lidocaine (JUV)
Trial: 8173183
Drug: Responders to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responders to therapy
Trial: 8173183
Drug: Non-responders to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-responders to therapy
Trial: 30685500
Drug: Ibuprofen advice
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen advice
Trial: 20809991
Drug: COMET +
RxNorm normalized name: Cometriq
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: COMET + regular therapy
Trial: 20809991
Drug: Regular therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular therapy only
Trial: 6716644
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (3 mg in 1.7 ml physiologic saline solution) administered through the epidural catheter.
Trial: 31034184
Drug: Liraglutide (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (up to 1.8 mg per day)
Trial: 24824118
Drug: LDT monotherapy
RxNorm normalized name: LDT
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: LDT monotherapy (600 mg orally, once daily)
Trial: 24824118
Drug: LDT +
RxNorm normalized name: LDT
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: LDT + ADV combination therapy (LDT 600 mg plus ADV 10 mg orally, once daily)
Trial: 24824118
Drug: LDT monotherapy
RxNorm normalized name: LDT
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: LDT monotherapy
Trial: 24824118
Drug: LDT +
RxNorm normalized name: LDT
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: LDT + ADV combination therapy
Trial: 22895856
Drug: Walnuts (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnuts (75 g/day)
Trial: 12198063
Drug: naproxen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen (500 mg)
Trial: 3266005
Drug: HbOC (Haemophilus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HbOC (Haemophilus influenzae type b mutant-diphtheria toxic conjugate vaccine)